MBRX — WP1066 Preclinical Study Results
Jul 1, 2025, 4:00:00 AM UTC
Summary
Moleculin Biotech, Inc. is set to report results from preclinical studies of WP1066, a STAT3 inhibitor, at Emory University. The studies focus on formulations for treating brain cancers, particularly glioblastoma. Results are expected in the second half of 2025, which may inform future clinical trials.
Company
MOLECULIN BIOTECH INC (MBRX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.moleculin.comSimilar Events
WP1066 and Radiation Therapy Phase 2 Trial Completion in Glioblastoma
A Phase 2 clinical trial evaluating WP1066, a STAT3 inhibitor, in combination with radiation therapy for newly diagnosed glioblastoma is expected to complete on December 27, 2028. The study, sponsored by Northwestern University, focuses on progression-free survival, tumor microenvironment changes, and safety in patients with MGMT-unmethylated glioblastoma. WP1066 is an investigational oral immunomodulatory agent targeting the STAT3 pathway, aiming to improve outcomes in malignant gliomas. The trial is registered as NCT05879250 and is currently recruiting.
trial completionPhase 3 Pivotal Trial Readout
IO Biotech is set to present data from its Phase 3 pivotal trial for the T-Win therapeutic cancer vaccines on September 30, 2025. This trial is crucial for the development of their immune-modulatory cancer therapies, which aim to address significant unmet needs in melanoma and other difficult-to-treat cancers. The company is also preparing for a Biologics License Application (BLA) and planning for commercialization of its first-in-class vaccine, Cylembio.
clinical readoutFinal Data Readout from MB-107 Trial
Moleculin Biotech, Inc. is set to report final data from the MB-107 trial evaluating Annamycin for treating soft tissue sarcoma lung metastases by the end of June 2025. Annamycin, also known as naxtarubicin, is a chemotherapy agent with Fast Track and Orphan Drug Designations from the FDA for its use in treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma. The trial's results are anticipated to provide insights into the drug's efficacy and safety profile in this patient population.
clinical readoutInitial Clinical Data Readout from Emi-Le Expansion Cohorts
Mersana Therapeutics plans to report initial clinical data from the expansion portion of its Phase 1 trial of Emi-Le, an antibody-drug conjugate targeting B7-H4, in patients with triple-negative breast cancer (TNBC) on July 1, 2025. This data will focus on patients who have received one to four prior lines of treatment, addressing a significant unmet medical need in this population.
clinical readout